Abstract: The present invention relates to 2-(1H-indolylsulfanyl)-aryl amine derivatives of the general formula I as the free base or salts thereof and their use for the treatment of affective disorders, pain, attention deficit hyperactivity disorder (ADHD) and stress urinary incontinence.
Type:
Grant
Filed:
July 13, 2005
Date of Patent:
March 16, 2010
Assignee:
H. Lundbeck A/S
Inventors:
Jan Kehler, Friedrich Kroll, Karsten Juhl
Abstract: The invention relates to compounds of the formula I A-B-Z ??I wherein the variables are as defined in the claims. The compounds are pro-drugs of A2A-receptor ligands with improved aqueous solubility, and are useful in the treatment of neurological and psychiatric disorders where an A2A-receptor is implicated.
Abstract: The present invention relates to 2-(1H-indolylsulfanyl)-benzyl amine derivatives of general formula (I): which are useful as SSRIs, and pharmaceutical compositions comprising the compounds.
Type:
Grant
Filed:
March 7, 2008
Date of Patent:
January 26, 2010
Assignee:
H. Lundbeck A/S
Inventors:
Jan Kehler, Karsten Juhl, Morten Bang Norgaard, Jimmy Sejberg
Abstract: Crystalline base of compound trans-1-((1R,3S)-6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine, processes for the preparation of purified free base or salts of this compound, pharmaceutical compositions comprising the base and medical use thereof, including for treatment of schizophrenia and other psychotic disorders.
Type:
Grant
Filed:
February 14, 2006
Date of Patent:
January 19, 2010
Assignee:
H. Lundbeck A/S
Inventors:
Benny Bang-Andersen, Heidi Lopez de Diego
Abstract: The present invention relates to morpholine and thiomorpholine derivatives or the general formula I or pharmaceutically acceptable salts thereof and their use.
Type:
Grant
Filed:
January 28, 2009
Date of Patent:
December 15, 2009
Assignee:
H. Lundbeck A/S
Inventors:
Christian Wenzel Tornoe, Mario Rottlander, Nikolay Khanzhin, Andreas Ritzen, William Patrick Watson
Abstract: The invention provides novel indane compounds which are useful in the treatment of affective disorders, pain disorders, attention deficit hyperactivity disorder (ADHD), cognitive disorders, substance abuse, smoking cessation and stress urinary incontinence.
Abstract: The present invention relates to compounds of formula I wherein the substituents are as defined below. The compounds of formula I are useful for the treatment of diseases such as schizophrenia, including both the positive and the negative symptoms of schizophrenia and other psychoses.
Type:
Grant
Filed:
April 27, 2004
Date of Patent:
November 3, 2009
Assignee:
H. Lundbeck A/S
Inventors:
Garrick P. Smith, Gitte K. Mikkelsen, Kim Andersen, Daniel R. Greve, Jorgen Eskildsen
Abstract: The present invention relates to 2-(1H-indolylsulfanyl)-benzyl amine derivatives of general formula (I): and pharmaceutical compositions comprising the compounds useful as SSRIs.
Type:
Grant
Filed:
December 21, 2005
Date of Patent:
July 21, 2009
Inventors:
Jan Kehler, Karsten Juhl, Jimmy Sejberg, Morten Bang Nørgaard
Abstract: The invention relates to compounds of the formula I wherein the variables are as defined in the claims. The compounds are useful in the treatment of a disease where a D4 receptor and/or a 5-HT2A receptor is implicated.
Abstract: The present invention relates to benzo[b]furane and benzo[b]thiophene derivatives of the general formula IV as the free base or salts thereof and their use.
Type:
Grant
Filed:
June 14, 2006
Date of Patent:
May 19, 2009
Assignee:
H. Lundbeck A/S
Inventors:
Jan Kehler, Karsten Juhl, Morten Bang Norgaard
Abstract: This invention provides isolated nucleic acids encoding mammalian SNORF33 receptors, purified mammalian SNORF33 receptors, vectors comprising nucleic acid encoding mammalian SNORF33 receptors, cells comprising such vectors, antibodies directed to mammalian SNORF33 receptors, nucleic acid probes useful for detecting nucleic acid encoding mammalian SNORF33 receptors, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding mammalian SNORF33 receptors, transgenic, nonhuman animals which express DNA encoding normal or mutant mammalian SNORF33 receptors, methods of isolating mammalian SNORF33 receptors, methods of treating an abnormality that is linked to the activity of the mammalian SNORF33 receptors, as well as methods of determining binding of compounds to mammalian SNORF33 receptors, methods of identifying agonists and antagonists of SNORF33 receptors, and agonists and antagonists so identified.
Type:
Grant
Filed:
September 15, 2005
Date of Patent:
April 14, 2009
Assignee:
H. Lundbeck A/S
Inventors:
Beth E. Borowsky, Kristine L. Ogozalek, Kenneth A. Jones
Abstract: The present invention relates to morpholine and thiomorpholine derivatives of the general formula I or pharmaceutically acceptable salts thereof and their use.
Type:
Grant
Filed:
December 21, 2005
Date of Patent:
March 10, 2009
Assignee:
H. Lundbeck A/S
Inventors:
Christian Wenzel Tornøe, Mario Rottländer, Nikolay Khanzhin, Andreas Ritzèn, William Patrick Watson
Abstract: This invention provides isolated nucleic acids encoding mammalian SNORF25 receptors, purified mammalian SNORF25 receptors, vectors comprising nucleic acid encoding mammalian SNORF25 receptors, cells comprising such vectors, antibodies directed to mammalian SNORF25 receptors, nucleic acid probes useful for detecting nucleic acid encoding mammalian SNORF25 receptors, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding mammalian SNORF25 receptors, transgenic, nonhuman animals which express DNA encoding normal or mutant mammalian SNORF25 receptors, methods of isolating mammalian SNORF25 receptors, methods of treating an abnormality that is linked to the activity of the mammalian SNORF25 receptors, as well as methods of determining binding of compounds to mammalian SNORF25 receptors, methods of identifying agonists and antagonists of SNORF25 receptors, and agonists and antagonists so identified.
Type:
Grant
Filed:
October 22, 2002
Date of Patent:
August 26, 2008
Assignee:
H. Lundbeck A/S
Inventors:
James A. Bonini, Beth E. Borowsky, Nika Adham, Noel Boyle, Thelma O. Thompson
Abstract: This invention provides an isolated nucleic acid encoding a human MCH1 receptor, a purified human MCH1 receptor, vectors comprising isolated nucleic acid encoding a human MCH1 receptor, cells comprising such vectors, antibodies directed to a human MCH1 receptor, nucleic acid probes useful for detecting nucleic acid encoding human MCH1 receptors, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding human MCH1 receptors, transgenic, nonhuman animals which express DNA encoding a normal or mutant human MCH1 receptor, methods of isolating a human MCH1 receptor, methods of treating an abnormality that is linked to the activity of a human MCH1 receptor, as well as methods of determining binding of compounds to mammalian MCH1 receptors.
Type:
Grant
Filed:
April 15, 2004
Date of Patent:
July 1, 2008
Assignee:
H. Lundbeck A/S
Inventors:
John A. Salon, Thomas M. Laz, Raisa Nagorny, Amy F. Wilson
Abstract: The present invention relates to novel compounds of formula I wherein the variable groups are as defined in the claims or a pharmaceutically acceptable acid addition salt thereof. The compounds of the invention are NK2 antagonists.
Type:
Grant
Filed:
December 16, 2002
Date of Patent:
June 10, 2008
Assignee:
H. Lundbeck A/S
Inventors:
Jan Kehler, Anders Poulsen, Berith Bjornholm, Friedrich Kroll, Morten Bang Norgaard
Abstract: The present invention concerns 1,2,4-triaminobenzene derivatives of the general formula I or pharmaceutically acceptable salts thereof and the use thereof.
Type:
Grant
Filed:
December 18, 2003
Date of Patent:
May 6, 2008
Assignee:
H. Lundbeck A/S
Inventors:
Mario Rottlander, Andreas Ritzen, Morten Bang Norgaard, Nikolay Khanzhin, Christian Wenzel Tornoe